Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 52Carcinoma, Non-Small-Cell Lung 28Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 24Stomach Neoplasms 19Recurrence 18Multiple Myeloma 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Ovarian Neoplasms 15Lung Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 11Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × Injections × Clear all
NCT06188624 2025-04-25

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
150 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡